India witnessing ‘V-shaped’ economic recovery since June: FinMin Report


India has been witnessing a ‘V-shaped’ recovery since June with the gradual easing of restrictions on economic activities, said a report.

“The sustained improvement in high frequency indicators ignite optimism of an improved performance in second half of the year,” it said.

The Monthly for December by the Department of Economic Affairs (DEA) also noted that the impending vaccination is set to spur the momentum in economic activity globally.

“The effective management of Covid-19 spread despite the festive season and onset of winter season, combined with sustained improvement in high frequency indicators and V-shaped recovery along with easing of lockdown restrictions distinguish Indian economy as one riding against the Covid-wave,” it said.

The agricultural sector remains the bright spot of Indian economy, with healthy year-on-year growth of 2.9 per cent in rabi sowing, accelerating tractor sales, and reservoirs’ live storage at 122 per cent of decadal average.

As per the DEA report, rise in minimum support prices accompanied by record procurement, and accelerated wage employment generation through MGNREGS, bodes well for rural incomes and bears testimony to PMGKY’s success in alleviating

Bharat Biotech chief takes on Serum Institute in Covid-19 vaccine war


A vaccine war has surfaced as India prepares for a massive inoculation drive to prevent the spread of coronavirus, which has killed more than 150,000 in the country. A day after two vaccines got restricted emergency use authorisation from the drug regulator, one of them — — has raised the pitch against competition. This comes in the backdrop of wide criticism against the approval granted to Bharat Biotech, which is yet to complete its phase three trial and present efficacy data.

At a hurriedly called virtual press conference, Krishna Ella, chairman and managing director of Hyderabad-based Bharat Biotech, on Monday raised questions over the approval given to Pune-headquartered (SII) for the Oxford-vaccine. Serum was the other company besides to get nod from the Drug Controller General of India (DCGI) on Sunday for Covid-19 vaccine.

Expressing confidence in his vaccine candidate Covaxin, Ella hit out at the trial done by AstraZeneca-Oxford, with which Serum Institute has a partnership for manufacturing the vaccine. He said if his firm had done a vaccine trial like AstraZeneca, the Indian regulator would have “shut down the company’’. He was

Is Britain a nation of risk-takers


The average Brit seems more than willing to take a risk now and again.

Everything from freefall parachuting to critical financial decisions, many of us appear content to undergo the risks to reap the rewards.

A study conducted by Portafina found that around half of U.K. adults are willing to take calculated risks, while only 15% of us tend to have a cautious trait. As for the gender split of risk-taking, men appear to be more accepting of risk (28%) than women (22%).

What Do We Take Risks On?

The five most common things people tend to take risks are as follows:

  • Making significant decisions based on gut feeling (44%).
  • Quitting a job before securing a new one (41%).
  • Speaking one’s mind, regardless of hurting someone’s feelings (38%).
  • Continuing to drive on a near-empty fuel tank (36%).
  • Spending without checking their bank balance beforehand (36%).

Other, more obscure, things that people have taken risks include car-surfing at speeds of over 50mph, traveling to the U.S.A. to stay with someone they knew only from an Internet forum, going to live with a new partner they’d just met online having never met before. Around one-in-six people admit to having gone skinny-dipping,

Subscribe Now